keyword
https://read.qxmd.com/read/38502425/the-effect-of-lacosamide-on-calcitonin-gene-related-peptide-serum-level-in-episodic-migraine-patients-a-randomized-controlled-trial
#1
JOURNAL ARTICLE
Shimaa Elgamal, Sherihan Rezk Ahmed, Mohamed M Nahas, Shimaa R Hendawy, Osama Elshafei, Mohamed G Zeinhom
BACKGROUND: Migraine affects 11-15% of people worldwide, and the calcitonin gene-related peptide (CGRP) is released during the migraine attack, producing pulsating pain of migraine. Also, lacosamide reacts with collapsin-response mediator protein 2, preventing its phosphorylation and leading to the inhibition of CGRP release in the trigeminal system. OBJECTIVE: The primary outcome was the difference in the serum level of CGRP-LI after three months of treatment with either lacosamide and ibuprofen or ibuprofen alone in episodic migraine patients...
March 19, 2024: Acta Neurologica Belgica
https://read.qxmd.com/read/38451604/safety-tolerability-and-dose-limiting-toxicity-of-lacosamide-in-patients-with-painful-chronic-pancreatitis-protocol-for-a-phase-1-clinical-trial-to-determine-safety-and-identify-side-effects
#2
JOURNAL ARTICLE
Evan L Fogel, Jeffrey J Easler, Ying Yuan, Dhiraj Yadav, Darwin L Conwell, Santhi Swaroop Vege, Samuel Y Han, Walter Park, Vanessa Patrick, Fletcher A White
BACKGROUND: Chronic abdominal pain is the hallmark symptom of chronic pancreatitis (CP), with 50% to 80% of patients seeking medical attention for pain control. Although several management options are available, outcomes are often disappointing, and opioids remain a mainstay of therapy. Opioid-induced hyperalgesia is a phenomenon resulting in dose escalation, which may occur partly because of the effects of opioids on voltage-gated sodium channels associated with pain. Preclinical observations demonstrate that the combination of an opioid and the antiseizure drug lacosamide diminishes opioid-induced hyperalgesia and improves pain control...
March 7, 2024: JMIR Research Protocols
https://read.qxmd.com/read/37849732/rhabdomyolysis-associated-with-newer-generation-anti-seizure-medications-asms-a-real-world-retrospective-and-pharmacovigilance-study
#3
JOURNAL ARTICLE
Zhenzhen Deng, Shengfeng Wang, Cuifang Wu
Objective: Rhabdomyolysis is a potentially fatal adverse reaction mostly triggered by certain medications. Few real-world studies have shown a clear association between newer-generation anti-seizure medications (ASMs) and rhabdomyolysis. We sought to quantify the risk and evaluate the clinical features and management of rhabdomyolysis associated with newer-generation ASMs. Methods: Data were retrieved from the US FDA Adverse Event Reporting System database (FAERS) from 2018 to 2022 on newer-generation ASMs to identify rhabdomyolysis events, and disproportionality analyses were conducted by estimating the reporting odds ratios (RORs) and corresponding 95% confidence intervals (CIs)...
2023: Frontiers in Pharmacology
https://read.qxmd.com/read/37782796/dual-pocket-inhibition-of-na-v-channels-by-the-antiepileptic-drug-lamotrigine
#4
JOURNAL ARTICLE
Jian Huang, Xiao Fan, Xueqin Jin, Liming Teng, Nieng Yan
Voltage-gated sodium (Nav ) channels govern membrane excitability, thus setting the foundation for various physiological and neuronal processes. Nav channels serve as the primary targets for several classes of widely used and investigational drugs, including local anesthetics, antiepileptic drugs, antiarrhythmics, and analgesics. In this study, we present cryogenic electron microscopy (cryo-EM) structures of human Nav 1.7 bound to two clinical drugs, riluzole (RLZ) and lamotrigine (LTG), at resolutions of 2...
October 10, 2023: Proceedings of the National Academy of Sciences of the United States of America
https://read.qxmd.com/read/37582688/trends-in-antiseizure-medication-prescribing-among-nursing-home-residents-with-and-without-a-seizure-diagnosis
#5
JOURNAL ARTICLE
Jonathan D Winter, J William Kerns, Katherine M Winter, Alicia Richards, Roy T Sabo
OBJECTIVES: Evaluate current prevalence and changes in prescribing of antiseizure medications (ASMs) in Virginia nursing homes for residents with and without seizures. METHODS: Retrospective cohort. De-identified claims extracted from the Virginia All-Payers-Claims-Database defined annual and biennial cohorts of all insured long-stay residents with and without any claims-based seizure diagnoses. ASM prescribing prevalence rates for these cohorts were analyzed from 2011 to 2016...
August 15, 2023: Neurologist
https://read.qxmd.com/read/37565715/the-effect-of-lacosamide-in-peripheral-neuropathic-pain-a-randomized-double-blind-placebo-controlled-phenotype-stratified-trial
#6
RANDOMIZED CONTROLLED TRIAL
Malin Erika Carmland, Melissa Dall Kreutzfeldt, Jakob Vormstrup Holbech, Peter Kolind Brask-Thomsen, Thomas Krøigård, Peter Nørregaard Hansen, Hatice Tankisi, Troels Staehelin Jensen, Flemming Winther Bach, Søren Hein Sindrup, Nanna Brix Finnerup
BACKGROUND: Neuropathic pain is common and difficult to treat. The sodium channel blocker lacosamide is efficacious in animal models of pain, but its effect on neuropathic pain in humans is inconclusive. METHODS: In a multicentre, randomized, double-blinded placebo-controlled phenotype stratified trial, we examined if lacosamide produced better pain relief in patients with the irritable nociceptor phenotype compared to those without. The primary outcome was the change in daily average pain from baseline to last week of 12 weeks of treatment...
January 2024: European Journal of Pain: EJP
https://read.qxmd.com/read/37473655/efficacy-and-tolerability-of-immediate-switch-from-sodium-channel-blockers-to-lacosamide
#7
JOURNAL ARTICLE
Orhan Talha Özgün, Melek Kandemir Yılmaz, Murat Mert Atmaca, Selda Keskin Güler, Eser Buluş, Arda Duman, Özlem Çelebi, Candan Gürses
Lacosamide (LCM) is a new-generation anti-seizure medication approved for monotherapy and add-on therapy for focal-onset epilepsy. It has novel pharmacodynamics and favorable pharmacokinetic qualities with good clinical response. This study aims to evaluate the effectiveness and tolerability of LCM when used in the immediate switch from sodium channel blockers in patients with focal-onset and generalized-onset epilepsies. This retrospective, multicenter observational study was conducted with adult patients who received LCM as mono- or polytherapy through immediate switch with 6 to 52 months follow-up...
July 18, 2023: Epilepsy & Behavior: E&B
https://read.qxmd.com/read/37325866/stability-indicating-normal-phase-hplc-method-development-for-separation-and-quantitative-estimation-of-s-enantiomer-of-lacosamide-in-pharmaceutical-drug-substance-and-tablet-dosage-form
#8
JOURNAL ARTICLE
Niroja Vadagam, Sharath Babu Haridasyam, Muvvala Venkatanarayana
Lacosamide (LA) is an antiepileptic medicine that is used to treat tonic-clonic seizures, partial-onset seizures, mental problems, and pain. A simple, effective, and reliable normal-phase liquid chromatographic technique was developed and validated to separate and estimate the enantiomer of (S-enantiomer) LA in pharmaceutical drug substance and drug product. Normal-phase LC was performed using USP L40 packing material (250 × 4.6 mm, 5 μm) and a mobile phase of n-hexane and ethanol at 1...
June 16, 2023: Biomedical Chromatography: BMC
https://read.qxmd.com/read/37270609/structural-mapping-of-na-v-1-7-antagonists
#9
JOURNAL ARTICLE
Qiurong Wu, Jian Huang, Xiao Fan, Kan Wang, Xueqin Jin, Gaoxingyu Huang, Jiaao Li, Xiaojing Pan, Nieng Yan
Voltage-gated sodium (Nav ) channels are targeted by a number of widely used and investigational drugs for the treatment of epilepsy, arrhythmia, pain, and other disorders. Despite recent advances in structural elucidation of Nav channels, the binding mode of most Nav -targeting drugs remains unknown. Here we report high-resolution cryo-EM structures of human Nav 1.7 treated with drugs and lead compounds with representative chemical backbones at resolutions of 2.6-3.2 Å. A binding site beneath the intracellular gate (site BIG) accommodates carbamazepine, bupivacaine, and lacosamide...
June 3, 2023: Nature Communications
https://read.qxmd.com/read/37265915/uncommon-progressive-systemic-tetanus-a-case-report
#10
Reinaldo Sanchez-Grillo, Esteban Zavaleta-Monestel, Eduardo Ruiz-Munguia, José Pablo Díaz-Madriz, Carolina Rojas-Chinchilla
Tetanus is a bacterial infection caused by the toxin of  Clostridium tetani . While it primarily affects newborns, people with incomplete vaccination schedules, it can also impact people of any age, especially in developing countries. Even though in the last 20 years several initiatives have been implemented worldwide to reduce the impact of this disease, regions like South Asia and sub-Saharan Africa have registered mortality rates highest since 2015-2019. In Latin America, regional immunization coverage rates were reported at 89% in 2017 for diphtheria-tetanus toxoid and pertussis (DTP-3), although Costa Rica has reported decreased coverage rates of the national immunization schedule from 2019 to 2021...
May 2023: Curēus
https://read.qxmd.com/read/37171159/synthesis-of-antiepileptic-drug-r-lacosamide-and-chronic-pain-reliever-s-lacosamide-from-chiral-glycine-enolate-equivalent
#11
JOURNAL ARTICLE
Prateek Bhamboo, Smritilekha Bera, Dhananjoy Mondal
A short enantioselective and azide-free synthesis of antiepileptic drug ( R )-lacosamide and pain reliever ( S )-lacosamide on a large scale has been articulated from an uncommon chiral synthon "glycine enolate equivalent of 4-benzyl- N -glycinyl oxazolidinone". Evans' asymmetric alkylation using N -( N -Boc-glycinyl) oxazolidinone was standardized to ensure the stereoselective formation of (Z)-enolate for a diastereofacial selection in the C -alkylation process of chiral glycine enolate equivalent with different alkyl halides such as methyl iodide, methoxymethyl chloride, benzyl bromide, p -NO2 C6 H4 CH2 Br, allyl bromide, and p -OCH3 C6 H4 CH2 Br in the presence of lithium diisopropyl amide at -78 °C in THF...
May 12, 2023: Journal of Organic Chemistry
https://read.qxmd.com/read/37036126/oral-lacosamide-for-the-treatment-of-refractory-trigeminal-neuralgia-a-retrospective-analysis-of-86-cases
#12
JOURNAL ARTICLE
Albert Muñoz-Vendrell, Raquel Tena-Cucala, Sergio Campoy, Belia García-Parra, Joan Prat, Sergio Martínez-Yélamos, Mariano Huerta-Villanueva
BACKGROUND AND OBJECTIVES: First-line treatment for trigeminal neuralgia (TN) is limited to carbamazepine and oxcarbazepine, and in refractory cases, alternatives are scarce. Lacosamide has been suggested as a valid option. In this study, we describe a series of patients who received oral lacosamide as treatment for TN after first-line drug failure. METHODS: In this retrospective descriptive cohort study, we included patients with refractory TN who attended a tertiary center between 2015 and 2021 and were prescribed oral lacosamide after first-line treatment failure...
April 2023: Headache
https://read.qxmd.com/read/36564853/neuronal-crmp2-phosphorylation-inhibition-by-the-flavonoid-naringenin-contributes-to-the-reversal-of-spinal-sensitization-and-arthritic-pain-improvement
#13
JOURNAL ARTICLE
Yue-Peng Jiang, Song Wang, Wei-Dong Lai, Xue-Qing Wu, Yan Jin, Zheng-Hao Xu, Aubin Moutal, Rajesh Khanna, Ki Duk Park, Zhi-Ming Shan, Cheng-Ping Wen, Jie Yu
BACKGROUND: Rheumatoid arthritis patients usually suffer from arthritic chronic pain. However, due to an incomplete understanding of the mechanisms underlying autoimmune disorders, the management of arthritic pain is unsatisfactory. Here, we investigated the analgesic effect and underlying mechanism of the natural flavonoid naringenin (NAR) in collagen-induced arthritis (CIA) pain. METHODS: NAR was injected (i.p.) once per day for 42 days after initial immunization, and rats were sacrificed on the 28th (the 21st day after final immunization, PID 21) and 42nd days (PID 35)...
December 23, 2022: Arthritis Research & Therapy
https://read.qxmd.com/read/36308490/off-label-pharmacological-treatment-for-neuropathic-pain-a-delphi-study-by-the-spanish-pain-society-neuropathic-pain-task-force
#14
JOURNAL ARTICLE
Ancor Serrano, Rafael Gálvez, Elena Paremés, Ana Navarro, Dolores Ochoa, Concepción Pérez
OBJECTIVES: The use of off-label pharmacotherapies for neuropathic pain (NP) is growing relating to the many unmet needs of patients. However, clinical guidelines fail to address it, and the available evidence is sparse and fragmented. We arranged a formal expert consensus to address this controversial issue and provide some guidance on judicious use. METHODS: A two-round standard Delphi survey that involved pain clinic specialists with experience in the research and management of NP was done over an ad hoc 40-item questionnaire prepared by the authors...
February 2023: Pain Practice: the Official Journal of World Institute of Pain
https://read.qxmd.com/read/36271873/palliative-care-and-end-of-life-care-in-adults-with-malignant-brain-tumors
#15
JOURNAL ARTICLE
Johan A F Koekkoek, Pim B van der Meer, Andrea Pace, Caroline Hertler, Rebecca Harrison, Heather E Leeper, Deborah A Forst, Rakesh Jalali, Kathy Oliver, Jennifer Philip, Martin J B Taphoorn, Linda Dirven, Tobias Walbert
BACKGROUND: This systematic review provides updated insights, from the published literature in the past 5 years, based on the 2017 European Association of Neuro-Oncology (EANO) guidelines for palliative care in adults with malignant brain tumors. It provides an overview of palliative care options, including during the end-of-life phase for patients with malignant brain tumors. METHODS: A systematic literature search was conducted from 2016 to 2021 focusing on four main topics: (1) symptom management, (2) caregiver needs, (3) early palliative care, and (4) care in the end-of-life phase...
March 14, 2023: Neuro-oncology
https://read.qxmd.com/read/36064434/imi2-paincare-biopain-rct2-protocol-a-randomized-double-blind-placebo-controlled-crossover-multicenter-trial-in-healthy-subjects-to-investigate-the-effects-of-lacosamide-pregabalin-and-tapentadol-on-biomarkers-of-pain-processing-observed-by-non-invasive-neurophysiological
#16
JOURNAL ARTICLE
Caterina Leone, Giulia Di Stefano, Giuseppe Di Pietro, Petra Bloms-Funke, Irmgard Boesl, Ombretta Caspani, Sonya C Chapman, Nanna Brix Finnerup, Luis Garcia-Larrea, Tom Li, Marcus Goetz, André Mouraux, Bernhard Pelz, Esther Pogatzki-Zahn, Andreas Schilder, Erik Schnetter, Karin Schubart, Irene Tracey, Inaki F Troconiz, Hans Van Niel, Jose Miguel Vela Hernandez, Katy Vincent, Jan Vollert, Vishvarani Wanigasekera, Matthias Wittayer, Keith G Phillips, Andrea Truini, Rolf-Detlef Treede
BACKGROUND: IMI2-PainCare-BioPain-RCT2 is one of four similarly designed clinical studies aiming at profiling a set of functional biomarkers of drug effects on specific compartments of the nociceptive system that could serve to accelerate the future development of analgesics. IMI2-PainCare-BioPain-RCT2 will focus on human spinal cord and brainstem activity using biomarkers derived from non-invasive neurophysiological measurements. METHODS: This is a multisite, single-dose, double-blind, randomized, placebo-controlled, 4-period, 4-way crossover, pharmacodynamic (PD) and pharmacokinetic (PK) study in healthy subjects...
September 5, 2022: Trials
https://read.qxmd.com/read/35852085/lacosamide-for-refractory-trigeminal-neuralgia-and-other-facial-pain-case-report
#17
JOURNAL ARTICLE
Shamin Masrour
OBJECTIVE: To demonstrate effect of lacosamide monotherapy in three patients with refractory facial pain of various etiologies. BACKGROUND: Many medications used to treat trigeminal neuralgia and other facial pain, including first- and second-generation anticonvulsants, are often ineffective or have intolerable side-effects. Lacosamide, a third-generation anticonvulsant, has fewer side-effects and is a potential treatment of facial pain. METHODS: Retrospective review of three patients treated with lacosamide for facial pain...
October 2022: Headache
https://read.qxmd.com/read/35762293/effects-of-mexiletine-and-lacosamide-on-nerve-excitability-in-healthy-subjects-a-randomized-double-blind-placebo-controlled-crossover-study
#18
JOURNAL ARTICLE
Titia Q Ruijs, Ingrid W Koopmans, Marieke L de Kam, Michiel J van Esdonk, Martin Koltzenburg, Geert Jan Groeneveld, Jules A A C Heuberger
Selective voltage-gated sodium channel blockers are of growing interest as treatment for pain. For drug development of such compounds, it would be critical to have a biomarker that can be used for proof-of-mechanism. We aimed to evaluate whether drug-induced changes in sodium conductance can be detected in the peripheral nerve excitability profile in 18 healthy subjects. In a randomized, double-blind, 3-way crossover study, effects of single oral doses of 333 mg mexiletine and 300 mg lacosamide were compared with placebo...
June 28, 2022: Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/35477602/a-case-of-possible-levetiracetam-induced-aseptic-meningitis-vs-viral-meningitis
#19
JOURNAL ARTICLE
P Brittany Vickery, J Kyle Roach, Stephen Vickery
INTRODUCTION: Meningitis causes inflammation of the meninges and when bacteria are not the cause may be considered aseptic. Drug-induced aseptic meningitis (DIAM) can arise from the use of certain medications. The pathophysiology of DIAM is not well understood. Within the antiepileptic medication class, only lamotrigine, carbamazepine, and levetiracetam have been associated with DIAM via documented cases. Common presentation of DIAM involves fever, headache, meningismus, and mental status changes (abnormal consciousness and focal neurological deficits)...
April 2022: CNS Spectrums
https://read.qxmd.com/read/35469475/intravenous-lacosamide-and-phenytoin-for-the-treatment-of-acute-exacerbations-of-trigeminal-neuralgia-a-retrospective-analysis-of-144-cases
#20
REVIEW
Albert Muñoz-Vendrell, Silvia Teixidor, Jacint Sala-Padró, Sergio Campoy, Mariano Huerta-Villanueva
BACKGROUND: Scant evidence is available on the use of intravenous pain treatment in acute exacerbations of trigeminal neuralgia. The aim of this descriptive study was to evaluate the effectiveness and security of intravenous lacosamide and phenytoin in the treatment of acute trigeminal neuralgia pain. METHODS: We reviewed patients who attended the emergency department of a tertiary hospital between 2012 and 2020 for exacerbations of trigeminal neuralgia pain and were treated with either intravenous phenytoin or lacosamide for the first time...
September 2022: Cephalalgia: An International Journal of Headache
keyword
keyword
50995
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.